All Johnson & Johnson Articles
Pharma’s Evolving 2024 Acquisition Spree – $ABBV $EPRX $GILD $JNJ $LLY $MRK $NVS $VRTX
Based on reports from The Wall Street Journal, major pharmaceutical companies are shifting their focus to smaller acquisitions in 2024, with all 17 deals announced in the first half of the year valued at $5 billion or less, reflecting a changing regulatory landscape and a more selective approach to ...
Aug 21, 2024
View Article
Janssen, Johnson & Johnson’s Dutch Arm, To Shut Down Most Of Vaccine Division – $JNJ $DIA $IBB $LTRN
Reportedly, Janssen, the Dutch subsidiary of Johnson & Johnson (JNJ) and a key contributor to the development of the one-shot COVID-19 vaccine, has announced its intention to shut down nearly all operations within its vaccine division. The company's decision aligns with prior...
Aug 29, 2023
View Article
Johnson & Johnson Investor Conference Call: Q2 Review & Insights $JNJ $DIA $SPY $INVO
Reportedly, Johnson & Johnson (JNJ) is scheduled to host an investor conference call on Thursday, July 20th at 8:30 a.m. ET to review the second-quarter results. The conference call will be hosted by Joaquin Duato, Chairman of the Board and CEO, Executive VP and CFO , Joseph J. Wolk along with J...
Jun 08, 2023
View Article
J&J’s Experimental Pill Shows Promise Against Dengue Virus – $JNJ $DIA $INVO
As per reports, Johnson & Johnson (JNJ) has developed an experimental pill for dengue that has shown promising results in animal studies. According to data published the pill was effective against all four types of the dengue virus in mice and prevented infection from two types in monkeys. This ...
Mar 22, 2023
View Article
Stay Informed. Stay Competitive.
Vista Partners offers an exclusive newsletter and content with daily, weekly, monthly and quarterly investing ideas, strategies, and marketing insights.
We value your privacy and will never share your information.
